TPM3 and neoplasm: Merestinib (dosed once daily at 12 mg/kg or 24 mg/kg) and entrectinib (dosed twice daily at 30 mg/kg) were evaluated in mouse tumor models with NIH-3T3 cells constitutively expressing wild-type TPM3-NTRK1, TPM3-NTRK1 with G595R or G667C mutation.